Peter Schraml

Peter Schraml


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MRMelanie Ruf
Melanie Ruf
HMHolger Moch
Holger Moch
PSPeter Schraml
Peter Schraml
In our study, we demonstrate that ccRCC cell lines with impaired function of pVHL to degrade HIFα express elevated levels of PD‐L1. In vitro analysis provided evidence that both reconstitution of pVHL and silencing of HIF2α, but not of HIF1α, lead to reduced PD‐L1 expression. The strong correlation of expression between the HIF2α‐specific HIF target Glut1 and PD‐L1 confirmed this finding in ccRCC cell lines and tissue. Soluble PD‐L1 levels remained constant in the sera of ccRCC patients regardless of the PD‐L1 expression status in their tumors. In conclusion, our data suggest PD‐L1 as HIF2α target, which is upregulated in pVHL deficient ccRCC. The combination of PD‐L1 targeting drugs with HIF inhibiting agents may be an additional option for the treatment of ccRCC.

5 September 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
RPRafal Pawłowski
Rafal Pawłowski
SMSarah M. Mühl
Sarah M. Mühl
TSTullio Sulser
Tullio Sulser
WKWilhelm Krek
Wilhelm Krek
HMHolger Moch
Holger Moch
PSPeter Schraml
Peter Schraml
Although von Hippel‐Lindau (VHL) tumor suppressor gene alterations dominate the genetic landscape of clear cell renal cell carcinoma (ccRCC), recent studies have identified new ccRCC genes, including SETD2, KDM6A, KDM5C, BAP1 and PBRM1. Strikingly, all these genes fall into a category of histone/chromatin regulators. Polybromo‐1 (PBRM1) is the second most frequently mutated gene after VHL; however, the clinical relevance of its loss in ccRCC has not yet been reported. Here, we analyzed the expression of PBRM1, the product encoded by PBRM1, in ccRCC cell lines and in more than 300 RCC tumor samples. The data were correlated with clinicopathological parameters and VHL mutation status. We found that a significant number of ccRCC cancer cell lines lack detectable PBRM1 expression. Loss of PBRM1 was predominant in the clear cell subtype of RCC (∼ 70%) and correlated with advanced tumor stage (p < 0.0001), low differentiation grade (p = 0.0002) and worse patient outcome (p = 0.025), but not with the VHL mutation status. Our results indicate a critical role for PBRM1 in the suppression of ccRCC progression. Moreover, the results suggest that functional inactivation of PBRM1 in the context of pVHL loss‐of‐function may represent a key event in facilitating the development of key aspects of an aggressive tumor behavior. Given the role of PBRM1 in chromatin modification, the gene expression pathways disrupted by the inactivation of this protein may lead to new treatment strategies for ccRCC.

1 January 2009 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
PSPeter Schraml
Peter Schraml
IFIan J. Frew
Ian J. Frew
CTClaudio R Thoma
Claudio R Thoma
GBGunther Boysen
Gunther Boysen
KSKirsten Struckmann
Kirsten Struckmann
HMHolger Moch
Holger Moch

28 February 2012 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
CDCarsten Denkert
Carsten Denkert
RKRalf Kronenwett
Ralf Kronenwett
WSWerner Schlake
Werner Schlake
KBKerstin Bohmann
Kerstin Bohmann
RPRoland Penzel
Roland Penzel
MDManfred Dietel
Manfred Dietel
Gene expression profiles provide important information about the biology of breast tumors and can be used to develop prognostic tests. However, the implementation of quantitative RNA-based testing in routine molecular pathology has not been accomplished, so far. The EndoPredict assay has recently been described as a quantitative RT-PCR-based multigene expression test to identify a subgroup of hormone–receptor-positive tumors that have an excellent prognosis with endocrine therapy only. To transfer this test from bench to bedside, it is essential to evaluate the test–performance in a multicenter setting in different molecular pathology laboratories. In this study, we have evaluated the EndoPredict (EP) assay in seven different molecular pathology laboratories in Germany, Austria, and Switzerland. A set of ten formalin-fixed paraffin-embedded tumors was tested in the different labs, and the variance and accuracy of the EndoPredict assays were determined using predefined reference values. Extraction of a sufficient amount of RNA and generation of a valid EP score was possible for all 70 study samples (100%). The EP scores measured by the individual participants showed an excellent correlation with the reference values, respectively, as reflected by Pearson correlation coefficients ranging from 0.987 to 0.999. The Pearson correlation coefficient of all values compared to the reference value was 0.994. All laboratories determined EP scores for all samples differing not more than 1.0 score units from the pre-defined references. All samples were assigned to the correct EP risk group, resulting in a sensitivity and specificity of 100%, a concordance of 100%, and a kappa of 1.0. Taken together, the EndoPredict test could be successfully implemented in all seven participating laboratories and is feasible for reliable decentralized assessment of gene expression in luminal breast cancer.

15 February 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MRMelanie Ruf
Melanie Ruf
CMChristiane Mittmann
Christiane Mittmann
ANAnna M. Nowicka
Anna M. Nowicka
AHArndt Hartmann
Arndt Hartmann
THThomas Hermanns
Thomas Hermanns
PSPeter Schraml
Peter Schraml
Purpose: CD70, a member of the TNF ligand superfamily, has been shown frequently overexpressed in clear cell renal cell carcinoma (ccRCC). The mechanisms of CD70′s upregulation and its role in ccRCC are unknown. Experimental Design: CD70 expression was immunohistochemically analyzed in 667 RCCs and RCC metastases. Von Hippel–Lindau gene (VHL) mutations, expression patterns of VHL protein (pVHL), hypoxia-inducible factor (HIF) α, and several HIF targets were studied in tissues and cell lines and correlated with CD70 overexpression. Gene promoter analysis was performed to confirm CD70 as HIF target gene. Consecutive tissue sections were immunostained to reveal the relation between CD70-expressing RCCs and tumor-infiltrating lymphocytes positive for the CD70 receptor (CD27). CD70-mediated release of soluble CD27 in RCC was assessed by coculture experiments and sera analysis of patients with RCC. Results: Elevated CD70 expression was seen in 80% of primary tumors and metastases of ccRCC and correlated with dysregulation of the pVHL/HIF pathway. In vitro analyses demonstrated that CD70 upregulation is driven by HIF. Furthermore, CD27+ lymphocytes preferentially infiltrate CD70-expressing ccRCCs. CD70-dependent release of soluble CD27 in cocultures may explain the high CD27 levels observed in sera of patients with CD70-expressing ccRCC. The combination of lymphocyte infiltration and CD70 expression in RCC was associated with worse patient outcome. Conclusion: Our findings demonstrate that in ccRCC, CD70 expression is regulated by HIF as a consequence of pVHL inactivation. Increased serum levels of CD27 suggest the existence of CD70-expressing ccRCC, thus representing a potential serum marker for patients suffering from this disease. Clin Cancer Res; 21(4); 889–98. ©2015 AACR.

9 June 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VTVerena Tischler
Verena Tischler
FFFlorian R Fritzsche
Florian R Fritzsche
PWPeter J Wild
Peter J Wild
CSCarsten Stephan
Carsten Stephan
HSHans-Helge Seifert
Hans-Helge Seifert
GKGlen Kristiansen
Glen Kristiansen
Background: Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far. Methods: Here, we evaluated periostin expression in prostate cancer cells and peritumoural stroma immunohistochemically in two independent prostate cancer cohorts, including a training cohort (n = 93) and a test cohort (n = 325). Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed. Results: In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%). Increased periostin expression in carcinoma cells was significantly associated with high Gleason score (p < 0.01) and advanced tumour stage (p < 0.05) in the test cohort. Whereas periostin expression was weak or absent in the stroma around normal prostate glands, strong periostin expression in tumour stroma was found in most primary and metastatic prostate cancers. High stromal periostin expression was associated with higher Gleason scores (p < 0.001). There was a relationship between stromal periostin expression and shortened PSA relapse free survival times in the training cohort (p < 0.05). Conclusions: Our data indicate that periostin up-regulation is related to increased tumour aggressiveness in prostate cancer and might be a promising target for therapeutical interventions in primary and metastatic prostate cancer.